Physician profile
Lawrence H Kwon
NPI 1598029571
$1,391.25
in general payments reported to CMS, 2019-2025
10 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $239 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $430.44 | 2025 | |
| Aurinia Pharma U.S., INC. | $275.53 | 2024-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $185.62 | 2025 | Jynarque |
| Vantive US Healthcare LLC | $144.66 | 2025 | Renal - Pd |
| Calliditas Therapeutics US INC. | $125.00 | 2023 | Tarpeyo |
| Ardelyx, INC. | $125.00 | 2024 | Xphozah 30 Mg |
| Ethicon US, LLC | $33.97 | 2025 | Vistaseal, Ethicon, Stratafix |
| Becton, Dickinson and Company | $29.00 | 2025 | Power-Trialysis |
| Apellis Pharmaceuticals, INC. | $28.07 | 2025 | |
| Amgen INC. | $13.96 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.